Working… Menu
Trial record 4 of 6 for:    "Hemophilia" | "HIV Protease Inhibitors"

First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01191372
Recruitment Status : Terminated
First Posted : August 30, 2010
Last Update Posted : October 23, 2017
Information provided by (Responsible Party):
Shire ( Baxalta now part of Shire )

Brief Summary:
The purpose of this study is to examine the safety, tolerability and the way the body handles various single and multiple doses of ARC19499 in patients with hemophilia.

Condition or disease Intervention/treatment Phase
Hemophilia Drug: placebo control Drug: ARC19499 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients
Study Start Date : September 2010
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: saline for injection Drug: placebo control
sterile saline for injection

Experimental: ARC19499 Low Dose Drug: ARC19499
Anti-tissue factor pathway inhibitor (TFPI) aptamer

Experimental: ARC19499 Mid Dose Drug: ARC19499
Anti-tissue factor pathway inhibitor (TFPI) aptamer

Experimental: ARC19499 High Dose Drug: ARC19499
Anti-tissue factor pathway inhibitor (TFPI) aptamer

Primary Outcome Measures :
  1. Pharmacokinetics (PK) of ARC19499 [ Time Frame: 2 weeks ]
    The PK profile of ARC19499 administered by single and multiple subcutaneous injections will be characterized. The bioavailability of subcutaneously injected ARC19499 relative to that of intravenously infused ARC19499 will be determined.

Secondary Outcome Measures :
  1. Coagulation system pharmacodynamic (PD) effects of ARC19499. [ Time Frame: 2 weeks ]
    The PD profile of ARC19499 with respect to the kinetics of thrombin generation and clot formation will be characterized.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Adult male patients ≥18 to ≤75 years of age.

  • Hemophilia of any type or severity.
  • Patients who are negative for hepatitis B surface antigen (HBsAg), and human immunodeficiency virus (HIV) I and II antibody tests at screening.
  • Male patients who, with their partners, are willing to use 2 effective, methods of contraception (i.e., for both self and partner) throughout the study and for at least 3 months after discontinuation of study drug treatment.
  • All patients must be capable of understanding and complying with the protocol and must have signed the informed consent document.

Exclusion Criteria:

  • Female patients;
  • If on a prophylactic coagulation factor concentrate regimen, inability or unwillingness to discontinue prophylaxis during participation in this study.
  • Existence of other co-existing bleeding disorder (e.g., von Willebrand Disease).
  • Medical history of venous or arterial thromboembolism.
  • Scheduled for elective surgical procedure during the conduct of this study.
  • Use of an investigational drug within 30 days of study entry.
  • Transaminase values > 3 x upper limit of normal (ULN) at time of screening.
  • Haemoglobin <12.0 g/dL.
  • Participants who, in the opinion of the Investigator, have a significant infection or known inflammatory process on screening.
  • Participants who have a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders.
  • Any medical condition the investigator believes would place the patient at increased risk as a result of participation in the study e.g. history of thromboembolic disease or stroke.
  • Any medication the investigator considers may increase the risk of adverse effects during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01191372

Layout table for location information
United Kingdom
London, United Kingdom
Sponsors and Collaborators
Baxalta now part of Shire
Layout table for investigator information
Study Director: Wing-Yen Wong, MD Baxter Healthcare Corporation

Layout table for additonal information
Responsible Party: Baxalta now part of Shire Identifier: NCT01191372     History of Changes
Other Study ID Numbers: ARC19499-001
2010-020373-17 ( EudraCT Number )
271101 ( Other Identifier: Baxter Healthcare Corporation )
First Posted: August 30, 2010    Key Record Dates
Last Update Posted: October 23, 2017
Last Verified: April 2013
Keywords provided by Shire ( Baxalta now part of Shire ):
Hemophilia A
Hemophilia B
Tissue Factor Pathway Inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Protease Inhibitors
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Lipoprotein-associated coagulation inhibitor
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Serine Proteinase Inhibitors
Enzyme Inhibitors
Factor Xa Inhibitors